Onco360
Highly Engaged Employees
Hospitals & Physicians Clinics · Kentucky, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
13410 Eastpoint Centre Dr Ste 101, Louis...Phone Number
(877) 662-6633Website
www.onco360.comRevenue
$266.7 MillionIndustry
About Onco360
Onco360 Org Chart
Is Onco360 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Onco360, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Onco360 recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Onco360 has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Onco360 is spiking on competitors!
Click to see if Onco360 had a recent Job posting/layoffs
Product Launch: Get notified when Onco360 launches new products
Congratulate Masked Content for being promoted to Masked Content at Onco360
Funding: Get notified immidiatlly once Onco360 has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Onco360
Compare insights from companies similar to Onco360, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Onco360 is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
Onco360 is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about Onco360.
Onco360 Tech Stack
A closer look at the technologies used by Onco360
Most Recent Scoops
Onco360 News & Media
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
LOUISVILLE, Ky., July 29, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU™ (vepdegestrant), which is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following aOnco360® Has Been Selected as a National Specialty Pharmacy Provider for JYLAMVO® (methotrexate) Oral Solution
LOUISVILLE, Ky, June 04, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Shorla Oncology for JYLAMVO® (methotrexate), indicated for the treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL), mycosis fungoides, adults with rheumatoid arthritis, adults with relapsed or refractory non-Hodgkin lymphoma, pediatric patients with polyarticular juvenile idiopathic arthritis, and adults with seOnco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution
LOUISVILLE, KY, June 02, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Shorla Oncology for IMKELDI® (imatinib) Oral Solution, indicated for the treatment of newly diagnosed Philadelphia-positive (Ph+ CML) chronic myeloid leukemia, Ph+ CML in blast crisis, accelerated phase or chronic phase after interferon-alpha therapy, adult and pediatric patients with Ph+ ALL, myelodysplastic/myeloproliferative disease (MDS/MOnco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Top Hospitals & Physicians Clinics Companies
Frequently Asked Questions Regarding Onco360
Founded in 2003, Onco360 provides health care services specializing in oncology pharmaceutical and care management services to physicians and patients. Onco360 is located in Kentucky.... Read More